YJ001 for Spray Use

DRUG2 trials

Sponsors

Yuejia Pharmaceuticals (USA), Inc., Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.

Conditions

Diabetic Peripheral Neuropathic PainSafety and Tolerability

Phase 1

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

CompletedNCT05451667

Yuejia Pharmaceuticals (USA), Inc.Safety and Tolerability

Start: 2022-08-15End: 2022-12-20Updated: 2023-01-04

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

RecruitingNCT06361108

Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Diabetic Peripheral Neuropathic Pain

Start: 2024-05-16End: 2026-06-30Target: 24Updated: 2025-08-13